Dr. Sinjini Sarkar

Qualification              : M. Pharm., Ph.D.

Specialization             : Pharmacology

E mail                         : sinjini.sarkar@nmims.edu

Phone                         : 022-42332000 (Extn- 2013)

Experience                 : 7+ years

(Research – 5+ years, Academics-2 years)

Dr. Sinjini Sarkar holds a Ph.D. (Pharmacy) from Jadavpur University, Kolkata, and was awarded the Young Scientist Fellowship from the Department of Health Research, Government of India, while working at Chittaranjan National Cancer Institute, Kolkata. Her expertise spans pharmacology, cancer biology, and molecular biology techniques including DNA/RNA/protein isolation, PCR, histopathology, immunohistochemistry, bioinformatics, and pharmacogenomics-based biomarker discovery. She has trained and supervised UG and PG students and served as faculty at reputed pharmacy institutions in Kolkata and Mumbai. Her recent work integrates experimental and computational approaches of gene expression profiling, and preclinical models to identify biomarkers and therapeutic targets in chemotherapy-associated complications and cancer progression.

Interest areas:

• Molecular Pharmacology
• Biomarker discovery in Oncology
• Clinical research

Research

• Publications – 12 (International-11 , National- 01)
• Book Chapters- 02
• Roy Pradhan, S., Mahata, S., Ghosh, D., Kumar Sahoo, P., Sarkar, S., Pal, R., & D. Nasare, V. (2020). Human Papillomavirus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism of Self-Clearance. IntechOpen. doi: 10.5772/intechopen.90197
• Sarkar, S., Mukherjee, S., Chatterjee, S., Basu, B., Karati, D., & Prajapati, B. (2025). Nanocarrier in Gene Therapy. In Nanocarriers for Nucleic Acids and Proteins (1st ed., pp. 24). CRC Press.
• Presentations- Total number (International- 02, National- 02)
• Government funded projects – 01
  • Completed (Study on MAD and BUB1 genes of spindle assembly checkpoint with response to primary adjuvant chemotherapy in advanced epithelial ovarian cancer, Department of Health Research, MoHFW, GoI, amount in Rs. 32,00,000/-Study site: Chittaranjan National Cancer Institute, Kolkata)
• University funded projects– 01 (Completed)
  • SVKM’s NMIMS sanctioned Rs. 2,84,338/- on 29^th July, 2024 under their Seed Funding Scheme for an intramural project, for the period of one year.

Conferences/Workshops/Seminars attended: 10

• Poster presentation: Sinjini Sarkar; Pranab Kumar Sahoo; Sutapa Mahata; Ranita Pal; Sushmita Ghosh; Tanmoy Bera; Vilas D. Nasare., MAD1L1 and MAD2L2 polymorphism in advanced ovarian carcinoma patients and its clinical impact, presented at FIGO XXIII World Congress of Gynaecology and Obstetrics held on 21-28th Oct, 2021. Abstract published: Int J Gynecol Obstet. 2021; 155(Suppl. 2):127–532. DOI: 10.1002/ijgo.13886 (IF: 4.4)
• Poster presentation: Sarkar, P.K. Sahoo, T. Mistry, R. Pal, S. Ghosh, T. Choudhury, S. Mahata, M. Vernekar, T. Bera, K.K. Mukherjee, P. Nath, V.D. Nasare, BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer, presented at ESMO Asia Congress held on 2-4th December, 2022. Abstract published: Annals of Oncology 2022; 33(Suppl. 9): S1508-S1509. DOI: https://doi.org/10.1016/j.annonc.2022.10.223 (IF: 51.769)
• Oral presentation: Sinjini Sarkar, Pranab Kumar Sahoo, Sushmita Ghosh, Sutapa Mahata, Ranita Pal, Tanuma Mistry, Trisha Choudhury, Manisha Vernekar, Puja Chatterjee, Partha Nath, Kalyan K Mukherjee, Vilas D Nasare. Clinical outcomes of paclitaxel-carboplatin chemotherapy with impact of mitotic checkpoint proteins in advanced ovarian cancer patients, presented at 5th International Conference on Nutraceuticals for Cancer and Other Chronic Disease (2022) Organized by Department of Zoology, University of Delhi, October 7-9,2022, IL-8 Page 48.
• Poster presentation: Sahoo, P. K., Sarkar, S., Mahata, S., Pal, R., Mistry, T., Ghosh, S., Choudhury, T., Bhowmick, A. K., Mukherjee, K. K., Datta, S., & Nasare,V. D. (2022). Clinical Efficacy and Quality of Life of Oral Cancer Patients Treated with Paclitaxel/Cisplatin/5-FU Vs Paclitaxel/Carboplatin Chemotherapeutic Regimens in a Tertiary Cancer Center in Eastern India, Journal of the National Comprehensive Cancer Network, 20(3.5), CLO22-081-CLO22-081. Retrieved Apr 7, 2022 (IF: 12.693)
• Poster presentation: Third prize winner, at National workshop on ‘Pharmacists for Healthy India’ organized by IPA, Bengal Branch and Jadavpur University on 27^th Nov, 2016. Topic of Poster: ‘Interference of autophagy in regulation of cytokine production: Influence on defense against microorganisms.’
• Attended the 2-days IIT Bombay BioPharma Summit, 2023 on 23^rd and 24^th Nov, 2023.
• Completed a 5-day Foundation Course in Clinical Research conducted by Tata Consultancy services at TCS, Thane for a Academia Industry Programme, in August, 2023.
• Participated in the Pre-conference Workshop on ‘Clinical Drug Research, Good Clinical Practice and Ethics’ at the 27^th Annual Conference, Indian Pharmacological Society, WB on 7^th Feb, 2018.

Academic activities

• Appointed as External referee conducting Viva-Voce examinations of B. Pharm (Pharmacology and Human Anatomy & Physiology) students from The Neotia University and NSHM College of Pharmaceutical Technology.
• Guest lecturer appointed by Pfizer for Pharmacy engagement programme in Mumbai location for pharmacists working at Breach Candy hospital, Mumbai in October 2023.
• Worked as an immediate supervisor for M.Sc (3) and B.Tech (2) students from University of Calcutta and KIIT, Bhubaneshwar for their 3-6 months dissertation.

Awards

• Awarded Young Scientist Fellowship (2018) from Department of Health Research, MoHFW, GoI
• Awarded College Topper, M. Pharm (2017), NSHM College of Pharmaceutical Technology, Kolkata
• Qualified Graduate Pharmacy Aptitude Test (2016)

Professional Memberships

• Registered Pharmacist, West Bengal State Pharmacy Council
• Member, Cochrane
• Member, European Society for Medical Oncology (ESMO), Switzerland

Recent Publications

1. Sarkar, Sinjini; Pal, Ranita; Choudhury, Trisha; Vernekar, Manisha; Chatterjee, Puja; Mukherjee, Kalyan Kusum; Nath, Partha; Behera, Santosh Kumar; Kumar, Sunil; Nasare, Vilas D. Checkpoint Genes in Check: Impact of BUB1, BUB1B, and MAD2 Alterations on the Treatment Outcomes of Advanced Ovarian Cancer. Journal of Current Oncological Trends 2(1):p 72-81, Jan–Jun 2025.
2. Pal R, Sarkar S, Choudhury T, Ghosh M, Vernekar M, Nath P, Nasare VD. Implication of microRNA-regulated PTEN expression in the clinico-pathology & survival outcomes in advanced ovarian cancer. Indian Journal of Medical research, (2025); 161: 521-531. (IF: 2.5)
3. Choudhury T, Pal R, Ghosh M, Chatterjee S, Sarkar S, Vernekar M, Nath P, Nasare VD. Clinicopathological insights and prognostic implications of DEK in association with apoptosis-regulating factors in ovarian cancer. Clin Transl Oncol. 2025 Nov;27(11):4192-4202. doi: 10.1007/s12094-025-03944-8. Epub 2025 May 20. PMID: 40392449. (IF: 2.8)
4. Sarkar S. Pathological role of RAGE underlying progression of various diseases: its potential as biomarker and therapeutic target. Naunyn-Schmiedeberg's archives of pharmacology, (2024).10.1007/s00210-024-03595-6. Advance online publication. https://doi.org/10.1007/s00210-024-03595-6. (IF: 3.1)
5. Sarkar S, Pal R, Choudhury T, Vernekar M, Nath P, Nasare VD. Genetic variations affect chemotherapy outcomes: A role of the spindle‑assembly checkpoint. Indian J Public Health 2024. (IF: 0.9)
6. Sahoo PK, Bhowmick AK, Sarkar S, Mahata S, Pal R, Mistry T, Ghosh S, Choudhury T, Kumar RS, Mondal S, Datta S, Nath P, Mukherjee KK, Nasare VD. Outcomes of 3-year follow up with induction vs first line chemotherapy in oral cancer patients: An observational hospital-based study. J Cancer Res Ther. 2024 Jan 22. doi: 10.4103/jcrt.jcrt_2179_22. Epub ahead of print. PMID: 38261440. (IF: 1.4)
7. Mistry T, Nath A, Pal R, Ghosh S, Mahata S, Kumar Sahoo P, Sarkar S, Choudhury T, Nath P, Alam N, Nasare VD. Emerging Futuristic Targeted Therapeutics: A Comprising Study Towards a New Era for the Management of TNBC. Am J Clin Oncol. 2024 Mar 1; 47(3):132-148. doi: 10.1097/COC.0000000000001071. Epub 2023 Dec 19. PMID: 38145412. (IF: 1.6)
8. Mahata S, Sahoo PK, Pal R, Sarkar S, Mistry T, Ghosh S, Nasare VD. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer. Med Oncol. 2022 May 15; 39(5):74. doi: 10.1007/s12032-022-01675-2. PMID: 35568774. (IF: 3.738)
9. Sarkar S, Sahoo PK, Pal R, Mistry T, Mahata S, Chatterjee P, Vernekar M, Mandal S, Bera T, Nasare VD. Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India. Support Care Cancer. 2022 Apr; 30(4):3371-3378. doi: 10.1007/s00520-021-06735-3. Epub 2022 Jan 6. PMID: 34988703. (IF-3.359)
10. Mahata S, Behera SK, Kumar S, Sahoo PK, Sarkar S, Fazil MHUT, Nasare VD. In-silico and in-vitro investigation of STAT3-PIM1 heterodimeric complex: Its mechanism and inhibition by curcumin for cancer therapeutics. Int J Biol Macromol. 2022 May 31; 208:356-366. Doi: 10.1016/j.ijbiomac.2022.03.137. Epub 2022 Mar 26. PMID: 35346675. (IF: 8.025)